West WH - Search Results

1

Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1.

Foglesong PD, Winkler MA, Price JO, Marshall GD, Reagh SH, Bush DA, Hixson KS, West WH. Foglesong PD, et al. Among authors: west wh. Cancer Immunol Immunother. 1989;30(3):177-84. doi: 10.1007/BF01669427. Cancer Immunol Immunother. 1989. PMID: 2598187 Free PMC article.

2

Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody cross-linked to OKT3.

Winkler MA, Price JO, Foglesong PD, West WH. Winkler MA, et al. Among authors: west wh. Cancer Immunol Immunother. 1990;31(5):278-84. doi: 10.1007/BF01740935. Cancer Immunol Immunother. 1990. PMID: 2142894 Free PMC article.

3

Principles of biotherapy and its application to the treatment of disseminated renal cancer.

O'Connor TE, West WH, Marshall GD, Orr DW, Lewis M, Oldham RK. O'Connor TE, et al. Among authors: west wh. Semin Surg Oncol. 1988;4(3):155-60. doi: 10.1002/ssu.2980040303. Semin Surg Oncol. 1988. PMID: 3055159 Review.

4

Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma.

West WH, Tauer KW, Yannelli JR, Marshall GD, Orr D, Lewis M, Birch R, Oldham RK. West WH, et al. Mol Biother. 1989;1(5):268-74. Mol Biother. 1989. PMID: 2619946

5

LAK cell therapy--clinical studies and future potential.

Marshall GD Jr, Schwartzberg LS, Tauer KW, Lee P, Holbert JM Jr, West WH. Marshall GD Jr, et al. Among authors: west wh. Prog Clin Biol Res. 1990;337:555-8. Prog Clin Biol Res. 1990. PMID: 2191342 Clinical Trial. No abstract available.

6

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. West WH, et al. N Engl J Med. 1987 Apr 9;316(15):898-905. doi: 10.1056/NEJM198704093161502. N Engl J Med. 1987. PMID: 3493433

7

Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.

West WH. West WH. Immunol Ser. 1989;48:79-92. Immunol Ser. 1989. PMID: 2488327 Clinical Trial. No abstract available.

8

Enhancement of human lymphokine-activated killer cell cytolysis and a method for increasing lymphokine-activated killer cell yields to cancer patients.

Yannelli JR, Thurman GB, Mrowca-Bastin A, Pennington CS, West WH, Oldham RK. Yannelli JR, et al. Among authors: west wh. Cancer Res. 1988 Oct 15;48(20):5696-700. Cancer Res. 1988. PMID: 3262411

9

Activation and expansion of tumor-derived activated cells for therapeutic use.

Maleckar JR, Friddell CS, Sferruzza A, Thurman GB, Lewko WM, West WH, Oldham RK, Yannelli JR. Maleckar JR, et al. Among authors: west wh. J Natl Cancer Inst. 1989 Nov 1;81(21):1655-60. doi: 10.1093/jnci/81.21.1655. J Natl Cancer Inst. 1989. PMID: 2795694

10

Tumor-derived activated cells: culture conditions and characterization.

Maleckar JR, Friddell CS, Lewko WM, Yannelli JR, West WH, Oldham RK. Maleckar JR, et al. Among authors: west wh. Immunol Ser. 1989;48:159-73. Immunol Ser. 1989. PMID: 2488319 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters